The past year or so has shown that Novo Nordisk (NYSE:NVO) isn't immune from seeing some serious challenges to its business. Between a serious setback in its insulin development program and nagging worries about incretins, 2013 isn't going to go down as a great year in the history of Novo Noridsk. All of that said, I have little doubt that the company will continue to be an uncommonly strong pharma company, with huge leverage to one of the fastest-growing diseases in the world. Although I think broadening both the diabetes business and the overall business would be beneficial, Novo Nordisk really doesn't have to do much to continue performing at a high level.
Please follow the link for more:
http://www.investopedia.com/stock-analysis/080813/novo-nordisk-getting-its-trial-fire-nvo-teva-sny-lly.aspx
Investopedia: Novo Nordisk Getting Its Trial By Fire
0 comments:
Post a Comment